Tianshili and French pharmaceutical companies sign a new drug cooperation research agreement on gene network

[China Pharmaceutical network enterprise news] on May 10, Tianjin Tianshili health city held a signing ceremony for the cooperation between Tianshili and pharnext S.A (hereinafter referred to as "pharnext") to carry out gene network new drug research Tianshili, pharnext and Daniel Cohen, founder of pharnext, agree to jointly establish a pharmaceutical R & D platform company (joint venture company) in Tianjin, China, based on the technical advantages of pharnext and Tianshili, to carry out technical innovation, product development and product commercialization management in the field of pharmaceutical products (photographed by Liu Qian at the signing ceremony) Yan Kaijing, executive chairman of Tianshili holding group, chairman of Tianshili Pharmaceutical Group Co., Ltd and Professor Daniel Cohen, CEO of pharnext company, signed the contract as representatives of both parties According to the announcement issued on May 9 by tisley, it is planned to invest 20 million euros in pharnext through its wholly-owned subsidiary, tisley (Hong Kong) Pharmaceutical Co., Ltd (hereinafter referred to as "Hong Kong tisley"), including 5 million euros for the newly issued common shares of pharnext (corresponding to 3.57% of the equity after investment) and 15 million euros for convertible bonds (115.3 can be obtained if the shares are successfully converted) 80000 shares, corresponding to 9.02% of the equity after investment, and 12.59% of the total shares of pharnext can be obtained According to the announcement, pharnext is a French company founded in 2007 and successfully listed on Euronext in July 2016 Pharnext is committed to the development of synergistic compound drugs, focusing on orphan drugs and common drugs for neurological diseases, including Charcot muscular dystrophy, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis The core technology is a unique platform of biological network pharmacology technology, which is used for virtual screening of drugs on the market to obtain compound drugs with independent intellectual property rights and very low dose combination for the treatment of other diseases At present, pharnext has two compound drugs in clinical stage, pxt3003 is used to treat CMT1A (Charcot atrophy 1a), pxt864 is used to treat ad The name of the joint venture company is proposed to be Tianshili international gene network Drug Innovation Center Co., Ltd with a registered capital of 142857142.85 yuan, of which Tianshili contributes 100000000 yuan in cash and pharnext contributes 42857142.85 yuan in technology price according to the terms and conditions of proprietary technology license, Mr Daniel Cohen has a stake in providing technical support The parties agree to transfer the right of clinical trial, product listing, manufacturing and sales of pxt3003 drug currently under development in Greater China to the joint venture company in one time (EUR 2 million) PXT3003 is a combination drug for treating 1A, and it is also known as hereditary motor sensory neuropathy (HMSN) It has obvious genetic heterogeneity The incidence rate in Europe and America is 1:3300~1:2500, and CMT1A incidence rate is 57%~37% of CMT At present, there is no clear therapeutic drug treatment for Charcot atrophy in the world Pxt3003 has a good therapeutic effect on CMT1A after phase II clinical verification in Europe and the United States After the synchronous development in Europe and the United States, FDA and EMA have granted orphan drug status At present, the second phase clinical trials of 80 patients and 6 centers have been completed, and the global synchronous third phase clinical research and development is in progress In the fourth quarter of 2015, the international phase III clinical research (27 clinical centers in Europe and the United States) was launched, and 300 patients with CMT1A (IA type of Charcot muscular atrophy) were enrolled for screening After the establishment of the joint venture company, it will continue to rely on the existing biomedical research and development platform, natural botanical medicine component database, the advantages of the Chinese market and pharnext's technical advantages in the research and development of combination drugs to reach the complementary advantages of both sides, build more disease biological network pharmacological models for the development of combination drugs, and promote the modern compound Chinese medicine with clear mechanism of action R & D.